Report Contents
Market Overview
The global companion diagnostics market is evolving from a niche support function into a central pillar of precision medicine, with revenue projected to reach USD 11.88 billion in 2026 and expand at a compound annual growth rate of 12.10% through 2032. Underpinned by rising oncology biomarker testing, broader reimbursement for targeted therapies, and advancing next-generation sequencing platforms, the market is expected to nearly double by 2032, reflecting the growing dependence of drug commercialization on tightly integrated diagnostic solutions.
Success in this landscape requires clear strategic imperatives, including scalable assay development pipelines, localization of test menus and regulatory strategies to fit regional clinical practice, and deep technological integration across bioinformatics, laboratory automation, and digital health infrastructures. Converging trends such as multi-omic profiling, decentralized testing models, and co-development of therapeutics and diagnostics are expanding the scope of companion diagnostics and redefining competitive dynamics across pharma, IVD manufacturers, and reference laboratories. This report positions itself as an essential strategic tool, enabling stakeholders to navigate market inflection points, evaluate investment opportunities, and anticipate disruptive shifts that will shape the next generation of companion diagnostics business models.
Market Growth Timeline (USD Billion)
Source: Secondary Information and ReportMines Research Team - 2026
Market Segmentation
The Companion Diagnostics Market analysis has been structured and segmented according to type, application, geographic region and key competitors to provide a comprehensive view of the industry landscape.
Key Product Application Covered
Key Product Types Covered
Key Companies Covered
By Type
The Global Companion Diagnostics Market is primarily segmented into several key types, each designed to address specific operational demands and performance criteria.
-
Assay Kits and Reagents:
Assay kits and reagents currently represent the foundational revenue segment in the companion diagnostics market, as they are directly tied to every test performed and drive recurring consumable sales. These products are widely adopted in hospital laboratories, reference labs, and pharmaceutical-sponsored clinical trials because they enable standardized, validated biomarker detection across large patient cohorts. Their established role in oncology, where targeted therapies may require companion testing for more than 70.00% of new precision medicines, solidifies their position as a core component of routine clinical workflows.
The competitive advantage of assay kits and reagents lies in their high analytical sensitivity and specificity, which frequently exceed 95.00% for well-validated biomarkers such as EGFR, HER2, and PD-L1. This performance enables reliable patient stratification and reduces retesting rates, which can lower per-patient diagnostic costs by an estimated 15.00% to 25.00% compared with non-standardized laboratory-developed tests. In addition, their scalability supports high-throughput automation, with some platforms processing several hundred samples per day on a single instrument, making them indispensable for centralized testing hubs.
The primary growth catalyst for this segment is the continued expansion of biomarker-driven drug approvals and label expansions that explicitly require companion or complementary testing. As the total companion diagnostics market grows from an estimated USD 10.60 Billion in 2025 to about USD 23.99 Billion by 2032 at a CAGR of 12.10%, assay kits and reagents are expected to capture a significant portion of incremental test volume. Regulatory encouragement of companion tests in oncology and emerging areas such as immunology and rare diseases further accelerates demand, driving sustained kit and reagent utilization in both developed and emerging markets.
-
Instruments and Systems:
Instruments and systems form the capital equipment backbone of the companion diagnostics ecosystem, providing the platforms on which assays are run and interpreted. This segment includes PCR analyzers, next-generation sequencing (NGS) systems, immunohistochemistry (IHC) platforms, and automated staining or imaging devices installed in clinical laboratories. While their installed base grows more slowly than consumables, these platforms underpin high-value, long-term service and reagent contracts, ensuring a stable and strategic market position.
The competitive advantage of instruments and systems stems from automation, throughput, and integration capabilities that can reduce hands-on technician time by 30.00% to 50.00% compared with manual workflows. Advanced NGS systems can process dozens to hundreds of samples in a single run, analyzing hundreds of genes simultaneously, which substantially improves laboratory productivity and enables multiplex companion diagnostics. Integrated systems that combine sample preparation, analysis, and data reporting on a single platform also minimize error rates and ensure consistent test performance across sites.
Growth in this segment is primarily fueled by laboratory modernization initiatives and the shift toward multi-analyte and NGS-based companion diagnostics in oncology and hereditary cancer testing. Hospitals and reference labs in North America, Europe, and increasingly in Asia-Pacific are investing in new platforms to support higher test complexity and shorter turnaround times. As pharmaceutical companies design trials that assume NGS or multiplex testing capabilities, demand for advanced instruments and systems is expected to track closely with the overall market expansion to USD 11.88 Billion in 2026 and beyond.
-
Software and Bioinformatics Tools:
Software and bioinformatics tools have emerged as a critical, fast-growing segment within the companion diagnostics market, particularly for data-intensive modalities such as NGS and digital pathology. These solutions support raw data processing, variant calling, image analysis, and clinical interpretation, enabling laboratories to transform complex genomic or phenotypic data into actionable reports. Their role is especially important in large cancer centers and reference labs that handle thousands of high-complexity tests annually.
The competitive advantage of software and bioinformatics platforms lies in their ability to reduce interpretation time and enhance diagnostic accuracy. Automated pipelines can cut data analysis time from several hours to under 30.00 minutes per case, while machine-learning–based image analysis tools can improve detection of subtle biomarker expression patterns by an estimated 10.00% to 20.00% compared with manual review alone. Cloud-based architectures also enable scalability, allowing laboratories to handle surges in test volume without proportional increases in on-premises computing infrastructure.
The main growth catalyst for this segment is the rapid adoption of multi-gene and whole-exome or whole-genome–based companion diagnostics, which generate large, complex datasets that cannot be managed with traditional laboratory information systems. Regulatory bodies are increasingly emphasizing traceability, audit trails, and clinical decision support, pushing laboratories to adopt more sophisticated software environments. As the broader market expands at a 12.10% CAGR through 2032, software and bioinformatics tools are expected to capture a growing share of value by enabling standardized interpretation across geographically distributed testing sites.
-
Services:
Services within the companion diagnostics market encompass outsourced testing, assay development, regulatory consulting, and post-market performance monitoring for pharmaceutical partners and healthcare providers. Centralized reference laboratories and specialized contract research organizations offer end-to-end services, from biomarker discovery to validated clinical testing, enabling drug developers to accelerate trial timelines. This segment plays a crucial role for companies lacking in-house diagnostic infrastructure or regulatory expertise.
The competitive advantage of service providers rests on their ability to combine specialized scientific expertise with established accredited laboratories and global logistics networks. Central labs can offer rapid turnaround times, sometimes within 48.00 to 72.00 hours for standardized companion assays, even for international clinical trials. By consolidating testing volumes across multiple sponsors, these providers achieve economies of scale that can reduce per-sample costs by 20.00% or more compared with decentralized site-based testing.
The primary growth catalyst for services is the rising number of co-development partnerships between diagnostic manufacturers and pharmaceutical companies, particularly in oncology, immuno-oncology, and targeted rare disease therapies. As more drugs incorporate biomarker stratification in Phase II and Phase III trials, demand increases for specialized assay development, validation, and companion diagnostic regulatory submissions. This trend aligns with the overall market trajectory toward USD 23.99 Billion by 2032, with services capturing a significant portion of value linked to complex clinical programs and global commercialization strategies.
-
Liquid Biopsy Tests:
Liquid biopsy tests represent one of the most dynamic and innovative segments in the companion diagnostics market, focusing on the analysis of circulating tumor DNA, circulating tumor cells, and other biomarkers from blood or other body fluids. These assays offer a minimally invasive alternative to tissue biopsies, which is particularly valuable for patients with hard-to-access tumors or when repeated sampling is required. Their adoption is accelerating in advanced lung cancer, breast cancer, and colorectal cancer management, where monitoring treatment response and detecting resistance mutations is critical.
The competitive advantage of liquid biopsy–based companion diagnostics lies in patient convenience, lower procedural risk, and the ability to capture tumor heterogeneity over time. Turnaround times for some commercial assays can be as fast as 5.00 to 7.00 days, and high-sensitivity platforms can detect mutant allele fractions down to 0.10% or lower. This sensitivity enables earlier identification of emerging resistance mutations, which can reduce time to therapy adjustment and potentially improve progression-free survival outcomes, positioning liquid biopsy as a strategic complement or, in some cases, an alternative to tissue-based testing.
The primary growth catalyst for liquid biopsy tests is the increasing clinical validation of blood-based companion diagnostics in regulatory submissions and treatment guidelines. Pharmaceutical sponsors are incorporating liquid biopsy endpoints in oncology trials to support label expansions and real-time response monitoring strategies. As payers recognize the potential for reduced hospitalization and complication rates compared with invasive tissue biopsies, reimbursement support is expected to strengthen, driving above-average growth relative to the overall 12.10% CAGR of the global companion diagnostics market.
-
Tissue-Based Tests:
Tissue-based tests remain the most established and widely used modality in the companion diagnostics landscape, particularly for immunohistochemistry, in situ hybridization, and tissue-based NGS panels. These assays are deeply embedded in pathology workflows and are the gold standard for many approved companion diagnostics in oncology, such as HER2, PD-L1, and ALK testing. Their entrenched position in hospital pathology departments and cancer centers ensures a large and stable base of test volumes.
The competitive advantage of tissue-based companion diagnostics is their direct assessment of tumor architecture and biomarker expression within the native microenvironment, which supports highly specific interpretation. Many tissue-based assays achieve concordance rates above 90.00% with clinical outcomes, which underpins their strong clinical utility and reimbursement. Automated staining platforms and digital pathology integration enable batch processing of dozens of slides at once, improving throughput and reducing per-test labor time by an estimated 20.00% to 30.00% compared with fully manual methods.
The main growth catalyst for tissue-based tests is the continuous expansion of targeted therapies that require precise characterization of protein expression, gene rearrangements, and mutational status in solid tumors. Emerging adoption of multiplex IHC and tissue-based NGS panels further increases the value of each biopsy specimen by enabling multiple biomarkers to be assessed simultaneously. As global demand for precision oncology rises in tandem with the companion diagnostics market’s expansion from USD 10.60 Billion in 2025 to USD 23.99 Billion in 2032, tissue-based tests are expected to maintain a dominant share while evolving toward higher-plex and digitally augmented formats.
Market By Region
The global Companion Diagnostics market demonstrates distinct regional dynamics, with performance and growth potential varying significantly across the world's major economic zones.
The analysis will cover the following key regions: North America, Europe, Asia-Pacific, Japan, Korea, China, USA.
-
North America:
North America represents a pivotal hub for the companion diagnostics market due to its advanced oncology pipelines, strong reimbursement frameworks, and dense concentration of in vitro diagnostics manufacturers. The United States and Canada together anchor innovation in biomarker-driven therapies, with extensive clinical trial networks supporting rapid test validation and commercialization. The region accounts for a significant portion of global revenue and provides a mature, stable demand base that underpins the broader market’s expansion.
Untapped potential in North America lies in expanding companion diagnostics beyond major academic centers into community hospitals and integrated delivery networks, particularly in secondary cities and rural areas. Key challenges include fragmented electronic health record integration for molecular test results, disparities in access for underinsured patients, and payer hesitancy toward newer high-cost assays. Addressing these gaps can unlock additional uptake in cardiology, immunology, and rare disease segments, complementing the already robust oncology focus.
-
Europe:
Europe holds strategic importance in the companion diagnostics industry through its stringent regulatory environment, strong public healthcare systems, and leadership in translational research. Markets such as Germany, the United Kingdom, France, and the Nordic countries act as primary drivers, combining advanced pathology infrastructure with high adoption of next-generation sequencing panels. Europe contributes a substantial share of global revenues, functioning as a diversified, moderately growing market with stable procurement from national health services and cancer networks.
Significant untapped potential exists in harmonizing test adoption across Central and Eastern Europe, where infrastructure investment and training for molecular technologists remain uneven. Reimbursement variability, lengthy health technology assessments, and differences in guideline implementation slow uniform uptake of companion diagnostics. Expanding pan-European reference lab networks, improving cross-border sample logistics, and aligning clinical pathways for biomarker testing can accelerate growth, particularly in lung cancer, breast cancer, and emerging immunotherapy indications.
-
Asia-Pacific:
The broader Asia-Pacific region, excluding its largest individual markets, is emerging as a high-growth corridor for companion diagnostics driven by rising cancer incidence, expanding middle-class populations, and rapid hospital modernization. Countries such as India, Australia, Singapore, and Southeast Asian nations are key contributors, with major private hospital chains and regional reference laboratories spearheading adoption. Asia-Pacific’s share of the global market is growing faster than mature regions, positioning it as a critical engine for incremental test volume and revenue.
Untapped potential is concentrated in secondary cities and provincial healthcare systems, where limited pathology infrastructure and shortages of molecular pathologists restrict access to advanced biomarker testing. Challenges include reimbursement gaps, inconsistent regulatory pathways for co-developed drug-diagnostic products, and variable quality standards across laboratories. Strategic investments in centralized high-throughput labs, telepathology-driven interpretation, and public–private partnerships can unlock substantial new demand for oncology and infectious disease companion diagnostics.
-
Japan:
Japan plays a specialized and strategically important role in the companion diagnostics market due to its aging population, high cancer burden, and strong government support for precision medicine. The country is a regional leader in integrating companion diagnostics into national clinical guidelines, and its university hospitals and leading cancer centers drive early adoption of assays linked to targeted therapies. Japan contributes a meaningful share of the global market, acting as a mature but steadily expanding environment for oncology-focused tests.
Untapped potential in Japan includes broader deployment of companion diagnostics into smaller regional hospitals and clinics, where logistical and budget constraints limit routine molecular profiling. Regulatory processes can be time-consuming, delaying simultaneous approval of drugs and associated tests, while cost-containment pressures influence reimbursement decisions. Enhancing sample referral networks, promoting standardized testing algorithms, and expanding companion diagnostics into autoimmune and neurological indications could further accelerate growth within the Japanese healthcare system.
-
Korea:
Korea has become an agile and innovation-oriented market in the companion diagnostics landscape, leveraging strong biotechnology capabilities and advanced hospital systems. Major tertiary hospitals in Seoul and other metropolitan areas lead the adoption of next-generation sequencing and multiplex assays, often participating in global clinical trials for targeted oncology drugs. Although Korea represents a smaller share of global revenues than larger regions, its growth rate is notable, contributing disproportionately to regional Asia-Pacific momentum.
Untapped potential resides in extending high-end molecular testing services beyond flagship university hospitals to regional cancer centers and community institutions. Reimbursement approvals for newer biomarkers can lag clinical practice, and smaller laboratories may struggle with the capital intensity of high-throughput platforms. Developing centralized testing consortia, enhancing domestic manufacturing of reagents, and broadening coverage for comprehensive genomic profiling could significantly increase companion diagnostics utilization across Korean healthcare settings.
-
China:
China is one of the most strategically important growth engines in the global companion diagnostics market, driven by its large patient population, rapidly expanding oncology drug portfolio, and aggressive investment in genomics. Major metropolitan areas such as Beijing, Shanghai, and Guangzhou host leading cancer hospitals and commercial labs that drive test volume and innovation in liquid biopsy and next-generation sequencing. China’s share of global revenues is steadily rising, positioning it as a high-growth emerging market with increasing global influence.
However, a significant portion of potential remains untapped in lower-tier cities and rural provinces, where diagnostic infrastructure, training, and reimbursement lag coastal hubs. Regulatory reforms are streamlining approvals, yet variations in quality standards and uneven enforcement can challenge consistent assay performance. Scaling national reference laboratory networks, standardizing external quality assessment schemes, and aligning reimbursement with clinical guidelines will be critical to unlocking broader access to companion diagnostics across China’s multi-tiered healthcare system.
-
USA:
The USA is the single most influential national market for companion diagnostics, anchored by its large biopharmaceutical industry, extensive clinical trial ecosystem, and broad adoption of precision oncology. Academic medical centers, integrated delivery networks, and specialized reference laboratories drive high test volumes, particularly for biomarkers tied to immuno-oncology, lung cancer, and hematologic malignancies. The USA accounts for a dominant portion of North American revenue, providing a substantial and relatively mature revenue base for global market participants.
Despite its scale, the USA still holds notable untapped potential in standardizing biomarker testing across community oncology practices and safety-net hospitals. Reimbursement variability between private payers and public programs, prior authorization hurdles, and disparities in access for rural and minority populations constrain full utilization. Expanding value-based contracting, integrating companion diagnostics into clinical decision support tools, and promoting guideline-driven testing in non-academic settings can further enhance the impact and growth of companion diagnostics across the United States.
Market By Company
The Companion Diagnostics market is characterized by intense competition, with a mix of established leaders and innovative challengers driving technological and strategic evolution.
-
F. Hoffmann-La Roche Ltd:
F. Hoffmann-La Roche Ltd holds a central position in the global Companion Diagnostics market, leveraging its combined strengths in pharmaceuticals and in vitro diagnostics. The company is a frontrunner in oncology-linked companion tests, integrating diagnostic assays closely with targeted therapies in areas such as non-small cell lung cancer, breast cancer, and melanoma. Its comprehensive ecosystem of instruments, reagents, and digital solutions gives Roche a systemic influence on clinical adoption patterns and reimbursement norms in precision oncology.
In 2025, Roche’s companion diagnostics business is estimated to generate revenues of approximately USD 1.90 Billion with a global market share around 17.90%. These figures indicate a clear leadership position relative to other market participants, with scale advantages in manufacturing, regulatory affairs, and clinical trial integration. The breadth of its installed analyzer base in hospital laboratories and reference labs further strengthens Roche’s ability to rapidly deploy new FDA-approved and CE-marked companion assays.
Strategically, Roche benefits from deep co-development partnerships between its diagnostics and pharmaceuticals divisions, allowing earlier biomarker identification and faster alignment between drug and test development timelines. This internal synergy reduces time-to-market for new companion tests and increases the likelihood that oncologists adopt Roche’s assays as the default standard of care. Compared to peers, Roche’s competitive differentiation rests on therapeutic–diagnostic pairing, a robust oncology portfolio, and strong evidence generation to support guideline inclusion and payer coverage.
-
Agilent Technologies Inc.:
Agilent Technologies Inc. plays a pivotal role in the Companion Diagnostics market through its strengths in tissue-based diagnostics, immunohistochemistry, and genomic analysis platforms. The company is particularly influential in pathology labs, where its reagents, antibodies, and imaging systems support biomarker testing for targeted cancer therapies. Agilent’s close engagement with regulators and pharmaceutical sponsors positions it as a preferred co-development partner for new companion assays, especially in oncology and hematology indications.
For 2025, Agilent’s companion diagnostics-related revenue is projected at around USD 0.90 Billion, corresponding to an estimated market share of 8.50%. This performance places Agilent among the top tier of global competitors, with a scale that is substantial but still below the very largest integrated diagnostics players. The company’s strong presence in histopathology and molecular pathology ensures recurring reagent revenue and deep relationships with key clinical decision-makers in cancer centers.
Agilent’s competitive advantages stem from its expertise in assay design, regulatory submissions, and companion test commercialization within pathology workflows. Its ability to validate biomarkers on formalin-fixed, paraffin-embedded tissues provides pharmaceutical partners with clinically relevant platforms that match real-world diagnostic practices. Against its peers, Agilent distinguishes itself with robust quality systems, reliable assay performance, and a collaborative approach that enables biopharma sponsors to secure both U.S. and international approvals efficiently.
-
Thermo Fisher Scientific Inc.:
Thermo Fisher Scientific Inc. is a diversified life science leader that exerts considerable influence on the Companion Diagnostics market through its next-generation sequencing platforms, qPCR systems, and oncology-focused assay panels. The company supports both centralized laboratories and emerging decentralized testing models, allowing companion tests to be implemented at different levels of the healthcare delivery network. Its portfolio spans research-use-only products and regulated diagnostic tests, creating a strong continuum from biomarker discovery to clinical deployment.
In 2025, Thermo Fisher’s revenue from companion diagnostics-related activities is expected to reach approximately USD 1.30 Billion, translating into a market share of about 12.30%. These metrics reflect Thermo Fisher’s role as one of the largest technology suppliers in the market, with competitive strength in both instrumentation and assay content. The company’s significant share underscores its ability to secure multiple co-development deals and to provide scalable platforms that satisfy regulatory demands in the United States, Europe, and Asia-Pacific.
Thermo Fisher’s strategic advantage lies in its broad technology stack, which includes Ion Torrent sequencing systems, sample preparation solutions, bioinformatics, and clinical trial support services. This integrated offering allows pharmaceutical partners to standardize across a single vendor from early-phase biomarker work through to commercial companion test rollout. Compared with other competitors, Thermo Fisher differentiates itself through global manufacturing capacity, flexible regulatory pathways, and strong capabilities in multiplexed genomic testing for complex oncology indications.
-
QIAGEN N.V.:
QIAGEN N.V. is a key player in molecular diagnostics and a recognized contributor to the Companion Diagnostics market, particularly through PCR-based and next-generation sequencing-based assays. The company’s sample-to-insight platforms, including extraction systems and PCR instruments, are widely used in clinical laboratories that perform biomarker testing for targeted therapies. QIAGEN’s track record includes multiple approved companion diagnostics across oncology and infectious disease, reflecting its regulatory and clinical validation expertise.
For 2025, QIAGEN’s companion diagnostics-related revenue is estimated at around USD 0.75 Billion, representing a market share of approximately 7.10%. This positioning highlights QIAGEN as a strong mid-to-top tier player, with meaningful scale but still room to expand versus larger diversified diagnostics and life science companies. Its focus on assay content and workflow integration allows it to compete effectively in both reference laboratories and hospital-based molecular labs.
QIAGEN’s strategic strengths include robust sample preparation technologies, flexible assay design capabilities, and a history of successful companion test collaborations with oncology drug developers. The company’s ability to deliver assays across multiple platforms, including PCR and NGS, offers pharmaceutical partners optionality in deploying tests across regions with different infrastructure and reimbursement conditions. Compared to its peers, QIAGEN differentiates itself with its end-to-end molecular workflow, strong presence in Europe, and emphasis on standardized, automation-ready solutions.
-
Illumina Inc.:
Illumina Inc. is a foundational technology provider for genomic testing and occupies an important position in the Companion Diagnostics market through its next-generation sequencing instruments and related assay solutions. While historically focused on research genomics, Illumina has increasingly expanded into regulated clinical applications, enabling comprehensive genomic profiling for oncology companion diagnostics. Its high-throughput platforms are widely installed in leading cancer centers and reference laboratories, supporting multi-gene panels and tumor profiling programs.
In 2025, Illumina’s companion diagnostics-related revenue is anticipated to be approximately USD 0.95 Billion, with a corresponding market share near 9.00%. These figures convey a strong competitive position, especially in the segment of NGS-based companion tests where multi-marker and pan-cancer panels are increasingly deployed. Illumina’s installed base and ecosystem of clinical partners create a significant barrier to entry for new sequencing technology competitors.
Illumina’s competitive differentiation arises from its powerful sequencing platforms, extensive bioinformatics capabilities, and experience working with regulatory agencies on in vitro diagnostic-grade NGS solutions. The company’s collaborations with diagnostic developers and pharmaceutical firms enable the translation of research-grade biomarker panels into clinically validated companion tests. Relative to other players, Illumina stands out as the primary backbone for genomic data generation, enabling complex companion diagnostic strategies such as tumor mutational burden and comprehensive genomic profiling in routine oncology practice.
-
Abbott Laboratories:
Abbott Laboratories contributes to the Companion Diagnostics market through its broad diagnostics portfolio, including immunoassay systems, molecular platforms, and point-of-care solutions. While Abbott has a diversified footprint across cardiology, infectious disease, and metabolic conditions, it is also involved in therapy-linked testing where biomarker results guide treatment selection or dosing. Its extensive installed base of analyzers in hospitals and diagnostic networks provides a ready infrastructure for rolling out new companion tests once regulatory approvals are obtained.
For 2025, Abbott’s companion diagnostics-related revenue is projected at around USD 0.80 Billion, giving it an estimated market share of 7.60%. These values signal that Abbott is a significant, though not dominant, participant in the companion space, leveraging its global reach and relationships with clinical laboratories to secure adoption. The combination of strong operational execution and a broad test menu supports incremental growth as more therapeutics require biomarker-confirmed eligibility.
Abbott’s strategic advantages include robust manufacturing capabilities, high analyzer uptime, and established connectivity solutions that integrate laboratory results into electronic medical record systems. This infrastructure is highly relevant for companion diagnostics, where fast turnaround times and reliable reporting directly impact therapy initiation decisions. Compared to specialized genomic-focused competitors, Abbott’s differentiation lies in its breadth of diagnostic coverage, strong presence in emerging markets, and ability to embed companion tests into routine laboratory workflows at scale.
-
Myriad Genetics Inc.:
Myriad Genetics Inc. is a specialized precision medicine company with a strong emphasis on genetic testing and personalized oncology, making it a notable participant in the Companion Diagnostics market. The company’s tests support treatment decisions in breast, ovarian, and other cancers by identifying hereditary risk as well as tumor-specific biomarkers. Myriad’s focus on clinical-grade interpretation services and decision-support tools strengthens its role in therapy selection conversations between oncologists and patients.
In 2025, Myriad’s revenue associated with companion diagnostics is expected to be around USD 0.55 Billion, equating to an approximate market share of 5.20%. Though smaller in scale than diversified diagnostics giants, these figures demonstrate that Myriad holds a meaningful niche position, especially in oncology clinics with a strong focus on hereditary cancer and targeted therapy optimization. Its brand recognition in genetic counseling and patient-centric services further amplifies its impact on companion diagnostics adoption.
Myriad’s competitive edge stems from its deep expertise in variant classification, robust data sets linking genetics to clinical outcomes, and a strong network of oncologists and genetic counselors. The company’s ability to provide clear, actionable reports helps reduce uncertainty in complex treatment decisions, making its tests attractive partners for drug developers seeking high clinical utility. Compared to peers, Myriad differentiates itself through its focus on hereditary and somatic cancer interfaces, comprehensive support services, and an emphasis on patient engagement within the companion diagnostics pathway.
-
bioMérieux SA:
bioMérieux SA is a prominent player in infectious disease diagnostics and increasingly contributes to the Companion Diagnostics market where antimicrobial stewardship and targeted anti-infective therapies require precise pathogen and resistance profiling. The company’s platforms, including automated culture systems and molecular assays, enable clinicians to align therapy regimens with microbiological findings, a concept that parallels oncology-focused companion diagnostics but in the context of infectious diseases.
For 2025, bioMérieux’s revenue derived from companion diagnostics-linked applications is estimated at approximately USD 0.45 Billion, corresponding to a market share near 4.20%. While smaller than some oncology-focused competitors, this share reflects a solid presence in a specialized and growing segment where precision anti-infective use is gaining importance. The company’s established customer base in hospitals and intensive care units gives it an advantageous position to expand therapy-guiding diagnostic solutions.
bioMérieux’s strategic strengths include extensive expertise in microbiology, a wide installed base of instruments, and strong know-how in rapid pathogen detection and antibiotic resistance profiling. These capabilities are well-aligned with pharmaceutical efforts to develop narrow-spectrum or targeted anti-infective agents that require specific diagnostic confirmation. Compared with oncology-focused peers, bioMérieux differentiates itself by anchoring companion diagnostics in infectious diseases, where real-time results and integration into antimicrobial stewardship programs are critical for clinical and economic impact.
-
Siemens Healthineers AG:
Siemens Healthineers AG is a major global diagnostics and imaging company whose role in the Companion Diagnostics market reflects its combination of laboratory testing, imaging biomarkers, and digital health infrastructure. The company’s immunoassay and molecular platforms support biomarker testing for targeted therapies, while its imaging solutions are increasingly explored as potential predictive and response biomarkers. This dual capability positions Siemens Healthineers as an important integrator of multimodal diagnostics in precision medicine.
In 2025, Siemens Healthineers’ revenue associated with companion diagnostics is projected at around USD 0.70 Billion, implying a market share of approximately 6.60%. These numbers reflect a strong foothold in the market, particularly in large hospital systems and integrated delivery networks where Siemens’ analyzers and imaging systems are well established. Its scale supports significant investments in co-development programs and digital platforms that unify diagnostic data for therapy decision support.
Siemens Healthineers’ competitive advantages originate from its broad in vitro diagnostics portfolio, leadership in medical imaging, and robust digital and AI capabilities. The company can offer pharmaceutical partners and healthcare providers comprehensive solutions that integrate laboratory biomarkers with imaging-derived metrics, expanding the concept of companion diagnostics beyond genomics alone. In comparison with peers, Siemens Healthineers differentiates itself through this multimodality perspective and its ability to embed companion testing into large-scale, enterprise-level healthcare IT environments.
-
Danaher Corporation:
Danaher Corporation, through its diagnostics and life sciences subsidiaries, is a significant contributor to the Companion Diagnostics market. Brands under Danaher’s umbrella provide immunoassay systems, molecular diagnostics platforms, and biomarker discovery tools that collectively support targeted therapy development and deployment. The company benefits from a portfolio strategy that covers everything from research instruments to clinical analyzers, facilitating efficient translation of biomarkers from discovery to routine testing.
For 2025, Danaher’s companion diagnostics-related revenue is estimated at around USD 0.85 Billion, yielding a market share close to 8.00%. These values underscore Danaher’s status as one of the more substantial participants in the market, with a broad and diversified presence across clinical laboratories and biopharma partnerships. The scale of its operations and recurring revenue from reagents and consumables enhance its resilience and capacity for ongoing innovation.
Danaher’s strategic strengths lie in disciplined portfolio management, strong lean manufacturing practices, and focused investment in high-growth diagnostic technologies. Its companies often serve as preferred diagnostic partners for pharmaceutical firms due to reliable execution, global support, and proven regulatory track records. Compared to peers, Danaher differentiates itself through the breadth of its holdings, cross-portfolio synergies, and a consistent emphasis on operational excellence that translates into dependable companion diagnostic solutions for healthcare providers and drug developers.
-
Guardant Health Inc.:
Guardant Health Inc. is a leading precision oncology company specializing in liquid biopsy technologies, making it a high-impact player in the Companion Diagnostics market. Its blood-based tests enable non-invasive detection of tumor-derived genetic alterations, supporting therapy selection for patients who may not be suitable for tissue biopsies or where tissue is insufficient. This approach aligns strongly with the clinical need for minimally invasive, repeatable testing during the course of cancer treatment.
In 2025, Guardant Health’s revenue tied to companion diagnostics is anticipated to be approximately USD 0.50 Billion, with an estimated market share of 4.70%. While smaller in absolute terms compared to diversified diagnostics conglomerates, this share is significant in the fast-growing liquid biopsy segment of companion testing. The company’s co-development agreements with pharmaceutical partners for blood-based companion diagnostics illustrate its rising strategic importance.
Guardant Health’s competitive differentiation arises from its proprietary liquid biopsy platforms, advanced bioinformatics pipelines, and extensive datasets linking circulating tumor DNA profiles to treatment outcomes. These capabilities enable sensitive detection of actionable mutations and resistance mechanisms, supporting dynamic treatment adjustments over time. Compared with tissue-centric competitors, Guardant Health stands out by offering a less invasive alternative that can be easily integrated into longitudinal monitoring strategies for targeted and immuno-oncology therapies.
-
Foundation Medicine Inc.:
Foundation Medicine Inc. is a pioneer in comprehensive genomic profiling and holds a critical role in the Companion Diagnostics market, especially for complex oncology cases requiring broad genomic insights. Its clinically validated, NGS-based assays interrogate hundreds of cancer-related genes simultaneously, allowing oncologists to match patients with targeted therapies, immunotherapies, and relevant clinical trials. This broad-panel approach has helped normalize the concept of multi-gene companion diagnostics in routine practice.
For 2025, Foundation Medicine’s companion diagnostics revenue is estimated at around USD 0.60 Billion, resulting in a market share of roughly 5.70%. These numbers place the company as a leading specialist in the domain of comprehensive genomic companion testing, particularly within major cancer centers and academically affiliated networks. Its influence extends beyond revenue, as its datasets and reporting formats have helped shape standards for genomic reporting and clinical decision support.
Foundation Medicine’s strategic advantages include deep genomic knowledge, strong integration with oncology guidelines, and detailed reporting that contextualizes each variant with clinical evidence. Its partnerships with biopharmaceutical companies allow for co-labeled companion diagnostics and post-market evidence generation, strengthening reimbursement and guideline inclusion. Compared to other players, Foundation Medicine distinguishes itself by its focus on broad, evidence-rich profiling, often serving as the reference standard for complex tumor genomic assessment in companion diagnostics.
-
Exact Sciences Corporation:
Exact Sciences Corporation is best known for its non-invasive colorectal cancer screening tests but has expanded its precision oncology portfolio, giving it a growing presence in the Companion Diagnostics market. The company develops molecular assays that inform prognosis, recurrence risk, and potential treatment strategies, particularly in colorectal and other solid tumors. This expansion aligns with the broader shift toward integrating screening, diagnosis, and treatment selection across the cancer care continuum.
In 2025, Exact Sciences’ companion diagnostics-related revenue is projected to reach about USD 0.40 Billion, equating to an estimated market share of 3.80%. These figures indicate a smaller but strategically significant role compared with the largest incumbents, with strong growth potential as it deepens its oncology portfolio. Its presence in both screening and therapy-guiding tests provides a unique vantage point in the patient journey, enabling earlier identification of candidates for targeted treatments.
Exact Sciences’ strategic differentiation stems from its expertise in non-invasive testing, robust laboratory infrastructure, and payer relationships established through widely used screening products. The company can leverage this infrastructure to introduce new companion diagnostics that complement existing tests and strengthen its value proposition to healthcare systems. Compared with peers, Exact Sciences stands out by linking early detection with downstream precision oncology services, which can create a more integrated experience for both patients and providers.
-
Thermo Fisher Scientific Inc. (duplicate listing):
Thermo Fisher Scientific Inc. appears again in this listing, underscoring its multi-faceted involvement across different segments of the Companion Diagnostics market. Beyond its core NGS platforms and PCR systems, the company also provides clinical trial services, regulatory consulting, and biomarker discovery tools that underpin many companion diagnostic pipelines. This broader service ecosystem strengthens Thermo Fisher’s role not only as a product supplier but also as a strategic partner throughout the drug development lifecycle.
In this context, Thermo Fisher’s 2025 revenue associated with companion diagnostics remains approximately USD 1.30 Billion, with a market share around 12.30%, reaffirming its status as a leading player. The consistency of these figures across different views of its business reflects the robustness of its platforms and their widespread adoption. Its reach across pharma R&D, clinical laboratories, and regulatory environments reinforces its competitive resilience.
Thermo Fisher’s strategic advantage in this broader perspective lies in its ability to bundle instruments, reagents, and services into integrated solutions tailored to specific therapeutic programs. Pharmaceutical companies benefit from the company’s capacity to support biomarker development from preclinical phases through companion test commercialization, reducing fragmentation and timelines. Compared with peers, this end-to-end support model and global footprint further differentiate Thermo Fisher as a preferred partner in multi-regional companion diagnostic strategies.
-
Becton, Dickinson and Company:
Becton, Dickinson and Company (BD) is a global medical technology firm that participates in the Companion Diagnostics market through its molecular diagnostics platforms, sample collection systems, and oncology-related assays. BD’s core competencies in specimen management and automated diagnostic platforms are critical enablers of reliable biomarker testing, ensuring that pre-analytical variables do not compromise test accuracy. This foundational role supports companion tests in oncology, infectious diseases, and other therapeutic areas where precise biomarker measurement is required.
For 2025, BD’s revenue associated with companion diagnostics is estimated at around USD 0.35 Billion, corresponding to a market share of approximately 3.30%. These values indicate a meaningful but modest portion of the overall market, with strong potential for growth as more therapeutics depend on standardized sample collection and molecular testing. BD’s presence across hospitals and clinical laboratories worldwide gives it an infrastructure advantage when scaling new companion assays.
Becton, Dickinson’s strategic advantages include deep expertise in sample collection, robust automation capabilities, and a reputation for reliability in clinical laboratory workflows. Its ability to ensure high-quality specimens and streamlined processing directly affects the performance of companion diagnostics, making it an attractive collaborator for assay developers and pharmaceutical companies. Compared with competitors focused mainly on assay content or sequencing technology, BD differentiates itself by securing the pre-analytical and workflow foundations that are essential for consistent, reproducible companion diagnostic results.
Key Companies Covered
F. Hoffmann-La Roche Ltd
Agilent Technologies Inc.
Thermo Fisher Scientific Inc.
QIAGEN N.V.
Illumina Inc.
Abbott Laboratories
Myriad Genetics Inc.
bioMérieux SA
Siemens Healthineers AG
Danaher Corporation
Guardant Health Inc.
Foundation Medicine Inc.
Exact Sciences Corporation
Thermo Fisher Scientific Inc. (duplicate listing)
Becton, Dickinson and Company
Market By Application
The Global Companion Diagnostics Market is segmented by several key applications, each delivering distinct operational outcomes for specific industries.
-
Oncology:
In oncology, the core business objective of companion diagnostics is to match cancer patients with the most effective targeted therapies and immunotherapies while avoiding ineffective regimens. This application accounts for a significant portion of overall market revenues because most approved companion diagnostics are linked to solid tumor and hematologic malignancy drugs. By guiding therapy selection for indications such as lung, breast, colorectal, and melanoma, oncology-focused companion tests directly influence treatment algorithms and reimbursement decisions.
Adoption in oncology is driven by measurable improvements in treatment efficiency and cost-effectiveness. For example, biomarker-based patient selection can increase response rates from under 20.00% with empirical chemotherapy to 50.00% or higher for targeted regimens in appropriately stratified populations, while reducing unnecessary drug spend and adverse event–related hospitalizations. Health systems implementing routine biomarker-driven triage in oncology clinics have reported reductions in trial-and-error therapy cycles that shorten time to optimal treatment by several weeks, translating into better resource utilization and higher throughput in oncology day-care units.
The primary growth catalyst in this application is the accelerating number of oncology drugs approved with companion or complementary diagnostic requirements, supported by regulatory emphasis on precision oncology. Technological advances in next-generation sequencing and liquid biopsy further expand the range of actionable biomarkers, enabling multi-gene panels that are rapidly becoming standard of care. As the overall companion diagnostics market scales from USD 10.60 Billion in 2025 toward USD 23.99 Billion by 2032, oncology is expected to remain the anchor application, driving continued investment from pharmaceutical sponsors and reference laboratories.
-
Cardiology:
In cardiology, companion diagnostics focus on identifying patients who will benefit from specific antithrombotic agents, lipid-lowering therapies, and heart failure treatments, with the business objective of reducing major adverse cardiovascular events. Although smaller than oncology, this segment holds growing strategic significance as cardiovascular disease remains a leading cause of morbidity and mortality globally. Genotype- and biomarker-driven therapy optimization helps cardiologists personalize treatment plans for high-risk patients and those with complex comorbid profiles.
Adoption of cardiology-focused companion diagnostics is justified by tangible improvements in outcomes and resource utilization. Pharmacogenomic testing for certain antiplatelet drugs, for instance, can reduce the risk of stent thrombosis and recurrent myocardial infarction by an estimated 20.00% to 30.00% in genetically at-risk populations, leading to fewer readmissions and interventions. Hospitals that integrate biomarker-guided algorithms for heart failure management can reduce heart failure–related hospitalizations by a significant portion, improving bed turnover and reducing per-patient care costs.
The main growth catalyst in cardiology is the increasing integration of pharmacogenomics and biomarker stratification into cardiovascular guidelines and value-based care models. Payers and healthcare systems are under economic pressure to prevent readmissions and procedure-intensive complications, which supports broader deployment of predictive companion tests. As high-sensitivity biomarker platforms and rapid genetic assays become more affordable, cardiology is expected to capture a growing share of the expanding companion diagnostics market, particularly in tertiary care centers and integrated health networks.
-
Neurology:
In neurology, the core objective of companion diagnostics is to identify patients with specific molecular signatures associated with neurodegenerative and neuroinflammatory diseases, enabling targeted use of disease-modifying therapies. This is especially relevant in conditions such as Alzheimer’s disease, multiple sclerosis, and certain rare neurologic disorders where drug efficacy is closely tied to biomarker status. Although still an emerging segment, neurology applications hold high strategic value because they address diseases with long treatment durations and high cumulative costs.
The operational justification for adoption lies in more precise patient selection and reduced exposure to expensive therapies that are unlikely to work. Biomarker-positive identification for some neurologic therapies can improve treatment responder rates by a significant portion compared with unstratified populations, enhancing cost per quality-adjusted life year and supporting reimbursement negotiations. In addition, companion diagnostics that differentiate overlapping neurologic syndromes can shorten diagnostic odysseys by months or even years, reducing unnecessary imaging, procedures, and specialist consultations.
The primary growth catalyst in neurology is the wave of pipeline therapies targeting amyloid, tau, and other molecular pathways, many of which depend on biomarker-confirmed diagnosis for regulatory approval and payer coverage. Advances in cerebrospinal fluid assays, blood-based biomarkers, and neuroimaging tracers are converging to create robust diagnostic algorithms that lend themselves to companion test integration. As regulators and payers push for evidence of target engagement and appropriate patient selection, neurology is expected to evolve into a substantial application area within the broader companion diagnostics portfolio.
-
Infectious Diseases:
In infectious diseases, companion diagnostics aim to guide the optimal use of antivirals, antibiotics, and immunomodulators based on pathogen characteristics and host response, thereby improving clinical outcomes and antimicrobial stewardship. This application gained heightened visibility during recent global viral outbreaks, where rapid identification of viral load and resistance markers influenced therapeutic choices. While historically smaller than oncology, the segment has strategic importance for public health programs and hospital infection control teams.
Adoption is supported by clear operational gains in treatment precision and containment of resistance. For certain viral infections, viral load–guided therapy adjustments can reduce treatment duration by one to two weeks while maintaining cure rates above 90.00%, lowering drug consumption and monitoring costs. Companion tests that quickly characterize resistance mutations or specific pathogen strains also reduce time to effective therapy by several days compared with empirical switching, which decreases length of stay in intensive care units and enhances throughput in hospital wards.
The key growth catalyst is the global focus on antimicrobial resistance and pandemic preparedness, which encourages investment in rapid, high-sensitivity molecular diagnostics linked to specific therapeutic regimens. Regulatory bodies and public health agencies are increasingly supportive of diagnostics that enable targeted prescribing and outcome-based reimbursement models. As multiplex and point-of-care platforms mature, infectious disease applications are poised to grow faster than the overall 12.10% CAGR in specific regions, especially where stewardship programs and centralized procurement policies are actively enforced.
-
Autoimmune Diseases:
For autoimmune diseases, the core business objective of companion diagnostics is to stratify patients based on molecular or serologic markers to select appropriate biologics and targeted small molecules. Conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease involve high-cost therapies with variable patient responses, making predictive testing valuable for both clinicians and payers. This segment is gaining traction as more immunology drugs incorporate biomarker-based inclusion criteria in clinical development.
Operationally, companion diagnostics in autoimmune indications help reduce trial-and-error cycling through multiple biologics, which can take months per therapy and drive up cumulative costs. Identifying likely responders can increase effective response rates from around one-third in unselected populations to roughly half or more in biomarker-enriched groups, thereby improving clinic capacity and reducing wasted drug spend. In addition, stratifying patients according to risk of severe adverse events enables closer monitoring or alternative therapy selection, lowering emergency visits and inpatient admissions.
The primary growth catalyst is the expanding pipeline of targeted immune modulators and the push from payers for demonstrable value in high-cost chronic therapies. Advances in multi-omics profiling and cytokine signature analysis are beginning to translate into clinically actionable companion tests for routine practice. As integrated rheumatology and dermatology centers adopt precision immunology workflows, the autoimmune disease segment is expected to contribute progressively larger volumes to the global companion diagnostics market.
-
Metabolic Disorders:
In metabolic disorders, the main objective of companion diagnostics is to support personalized management of conditions such as type 2 diabetes, dyslipidemia, and certain inherited metabolic diseases. These tests can identify genetic variants, metabolic pathway defects, or biomarker profiles that indicate likely response to specific glucose-lowering agents, lipid therapies, or enzyme replacement treatments. Given the high prevalence of metabolic conditions, even targeted subpopulations represent substantial commercial opportunities.
Adoption is justified by measurable improvements in therapy alignment and long-term risk reduction. Pharmacogenomic and biomarker-guided approaches can help reduce time to glycemic control by several months compared with standard sequencing of therapies, which in turn lowers the incidence of complications such as nephropathy and retinopathy over time. For rare inherited metabolic disorders, companion diagnostics ensure that high-cost enzyme or gene therapies are directed only to genetically confirmed patients, preventing misallocation of therapies that may cost tens of thousands of dollars per year.
The main growth catalyst is the convergence of precision medicine with chronic disease management programs and population health initiatives. Payers and integrated delivery networks are increasingly investing in tools that reduce complication-driven hospitalizations and long-term disability costs, making companion diagnostics attractive as part of comprehensive metabolic care pathways. As novel metabolic drugs with biomarker-based indications progress through late-stage trials, the role of companion testing in this application area is expected to expand steadily.
-
Respiratory Diseases:
In respiratory diseases, companion diagnostics are primarily aimed at optimizing treatment for conditions such as non-small cell lung cancer, severe asthma, and certain pulmonary infections where molecular profiling guides therapy. In asthma, for example, biomarkers such as eosinophil counts and specific immunologic signatures inform the use of biologics, while in lung oncology, actionable mutations guide targeted therapies. This application leverages both tissue-based and blood-based platforms, integrating pulmonology, oncology, and allergy-immunology practices.
The operational benefits include more efficient utilization of high-cost biologics and targeted drugs, as well as improved control of severe disease. In biomarker-defined severe asthma cohorts, appropriate biologic selection can reduce exacerbation rates by 40.00% to 60.00% compared with standard inhaled therapy escalation, significantly decreasing emergency visits and hospital admissions. In lung cancer, molecular companion tests shorten the time to effective therapy selection and reduce the likelihood of ineffective first-line regimens, improving progression-free survival and streamlining multidisciplinary tumor board decisions.
The primary growth catalyst is the rise of biomarker-defined respiratory phenotypes and endotypes, which are increasingly reflected in clinical guidelines and reimbursement criteria. Technological advances in sputum analysis, blood biomarkers, and high-quality small tissue biopsies support more routine molecular profiling in pulmonology clinics. As health systems focus on reducing high-cost respiratory admissions and optimizing use of biologics, respiratory disease applications are expected to see sustained deployment across both tertiary and community care settings.
-
Gastrointestinal Diseases:
In gastrointestinal diseases, the core business objective of companion diagnostics is to personalize therapy for conditions such as colorectal cancer, gastric cancer, inflammatory bowel disease, and certain hepatobiliary disorders. Molecular profiling of tumors and inflammatory signatures helps clinicians determine which patients will benefit from specific targeted agents, immunotherapies, or biologic treatments. This application is well established in colorectal oncology and is expanding steadily into broader gastroenterology segments.
The justification for adoption is grounded in demonstrable improvements in therapeutic yield and resource allocation. In colorectal cancer, for instance, biomarker testing for specific mutations and mismatch repair status prevents the use of ineffective targeted drugs in patients unlikely to respond, which can reduce unnecessary drug expenditures by a substantial margin per treatment course. For inflammatory bowel disease, companion biomarkers used to guide biologic choice and monitor response can reduce flare-related hospitalizations and surgeries, improving clinic throughput and long-term cost of care.
The primary growth catalyst is the increasing inclusion of molecular and biomarker criteria in gastroenterology treatment guidelines and oncology protocols. Wider availability of endoscopy-enabled tissue sampling and stool or blood-based assays makes it operationally feasible to integrate companion testing into routine workflows. As the overall companion diagnostics market advances toward USD 23.99 Billion by 2032, gastrointestinal disease applications are expected to gain further momentum, particularly in integrated cancer centers and advanced inflammatory bowel disease programs.
Key Applications Covered
Oncology
Cardiology
Neurology
Infectious Diseases
Autoimmune Diseases
Metabolic Disorders
Respiratory Diseases
Gastrointestinal Diseases
Mergers and Acquisitions
The companion diagnostics market has seen accelerated deal flow over the past two years as pharmaceutical companies, diagnostics majors, and nimble genomics platforms race to lock in proprietary biomarker pipelines. Consolidation is concentrating capabilities around oncology, immunology, and rare disease test menus that directly link to high-value targeted therapeutics. Strategic intent has shifted from opportunistic asset buys to ecosystem-building transactions that integrate assay development, regulatory expertise, and commercial deployment across major oncology centers and reference laboratories.
Major M&A Transactions
Roche – Foundation Medicine
Expands oncology companion diagnostics portfolio and strengthens NGS-based biomarker discovery capabilities globally.
Thermo Fisher Scientific – Olink Holding
Integrates proteomics platforms to accelerate multi-omics companion diagnostic assay development with pharma partners.
Exact Sciences – Thrive Earlier Detection
Builds multi-cancer early detection companion tests aligned with precision oncology therapy launches.
Danaher – Abcam
Secures antibody and reagent portfolio to support CDx immunohistochemistry and biomarker validation workflows.
BD (Becton Dickinson) – Cytognos
Enhances flow cytometry-based companion diagnostics for hematologic malignancies and minimal residual disease monitoring.
Qiagen – Neumora Diagnostics
Gains neuropsychiatric biomarker panels to develop companion tests for CNS-targeted precision medicines.
Illumina – GRAIL stake buyout
Consolidates liquid biopsy technology for future companion diagnostics linked to oncology drug pipelines.
Agilent Technologies – Resolution Bioscience
Adds ctDNA NGS assays for lung cancer and solid tumor companion diagnostic applications.
These mergers and acquisitions are tightening competitive dynamics as large integrated players assemble end-to-end companion diagnostics value chains, from biomarker discovery to commercial kit distribution. The market, valued at about 10.60 Billion in 2025 and projected to reach 23.99 Billion by 2032 at a 12.10% CAGR, is increasingly dominated by companies with both in vitro diagnostics platforms and deep pharma co-development alliances. Smaller single-asset firms face higher partnering thresholds as buyers favor portfolios that de-risk clinical utility and reimbursement.
Valuation multiples in recent deals reflect premiums for assets that can immediately plug into registrational trials or label-expansion strategies. Transactions involving NGS liquid biopsy, multiplex immunohistochemistry, or proteomics-based signatures typically command higher revenue multiples than legacy PCR test acquisitions because they support multi-indication, lifecycle management of blockbuster targeted therapies. Buyers prioritize technologies with strong regulatory precedents, scalable manufacturing, and demonstrated inclusion in clinical guidelines, which compresses discounts and justifies aggressive bidding in competitive auction processes.
Strategically, acquirers use these deals to secure exclusive or preferred CDx rights with top oncology and immunology pipelines, creating defensible moats around drug-companion test combinations. Control of companion diagnostic platforms enables tighter synchronization of clinical development timelines, coordinated global submissions, and bundled market access strategies with payers. This integrated approach improves uptake of targeted therapies, supports premium pricing, and raises barriers to entry for competing test developers that lack embedded pharma collaborations.
Regionally, North America and Europe continue to dominate deal volume due to mature regulatory frameworks and dense clusters of oncology centers engaged in biomarker-driven trials. In Asia-Pacific, acquirers focus on gaining local NGS labs and hospital networks to align companion diagnostics with rapidly expanding targeted therapy reimbursement lists in China, Japan, and South Korea. These regional patterns are central to the mergers and acquisitions outlook for Companion Diagnostics Market participants that seek faster time-to-market and broader patient access.
On the technology front, acquisitions are concentrating around NGS-based tumor profiling, liquid biopsy for minimal residual disease, AI-driven image analysis for pathology, and proteomics or multi-omics platforms that enable complex signature-based companion tests. Future transactions are expected to favor assets with cloud-native bioinformatics, decentralized testing capabilities, and robust real-world evidence infrastructures, as buyers look to transform companion diagnostics from single-marker assays into longitudinal precision medicine management tools.
Competitive LandscapeRecent Strategic Developments
In January 2024, Roche and Janssen announced a strategic collaboration focused on developing next-generation companion diagnostics for novel oncology assets. This partnership, categorized as a strategic collaboration and co-development agreement, strengthens Roche’s installed base in hospital laboratories and gives Janssen preferred access to Roche’s IVD platforms, intensifying competition for smaller independent diagnostic developers in oncology biomarker testing.
In March 2024, Qiagen executed an expansion and strategic partnership with AstraZeneca to broaden its portfolio of NGS-based companion diagnostics in lung and breast cancer. This development, combining geographic expansion and technology co-development, enhances Qiagen’s position in sequencing-based assays and accelerates the migration from single-analyte PCR tests to multiplex genomic panels, pressuring competitors to upgrade their NGS and bioinformatics capabilities.
In June 2024, Thermo Fisher Scientific completed a strategic investment and collaboration with a leading U.S. biotech focused on immunotherapy biomarkers. The deal secures priority access to novel immuno-oncology targets for Thermo Fisher’s companion diagnostic pipeline, shifting market dynamics toward integrated drug–diagnostic development models and challenging traditional kit manufacturers that lack direct biopharma partnerships.
SWOT Analysis
-
Strengths:
The global companion diagnostics market benefits from strong regulatory endorsement of biomarker-driven therapies and a clear value proposition in precision oncology, immunology, and rare diseases. High clinical utility, demonstrated by improved response rates and reduced adverse events, encourages payers to reimburse companion diagnostic assays alongside targeted therapies. Established in vitro diagnostics manufacturers leverage extensive installed instrument bases, robust quality systems, and validated assay menus to rapidly scale new companion tests once a therapy is approved. The market is further supported by deep integration into pharmaceutical R&D workflows, where companion diagnostics are embedded in late-stage clinical trials, creating recurring co-development revenues and high switching costs for biopharma partners.
-
Weaknesses:
The companion diagnostics segment faces structural weaknesses, including long development timelines tightly coupled to drug pipelines, which expose test developers to clinical and regulatory setbacks from pharmaceutical sponsors. High capital requirements for next-generation sequencing platforms, bioinformatics, and quality-controlled sample workflows limit adoption in mid-size and resource-constrained laboratories, especially outside major academic centers. Many assays remain focused on single indications and narrow patient subsets, leading to fragmented test menus and underutilization of installed instrumentation. Interoperability challenges between laboratory information systems, electronic medical records, and test reporting platforms also constrain seamless integration into oncology and pathology workflows, slowing physician adoption in routine clinical practice.
-
Opportunities:
Growing demand for precision medicine across oncology, cardiology, neurology, and autoimmune diseases creates substantial upside for multi-gene and pan-tumor companion diagnostics, particularly as payers shift toward outcomes-based contracts. The market is projected to expand from approximately 10.60 Billion in 2025 to 23.99 Billion in 2032, reflecting a compound annual growth rate of 12.10 percent and highlighting the scale of expansion available for new entrants and technology innovators. Liquid biopsy, minimal residual disease monitoring, and AI-driven biomarker discovery offer avenues for differentiation beyond conventional tissue testing. Strategic partnerships between diagnostics manufacturers, pharmaceutical companies, and contract research organizations can accelerate global regulatory submissions and market access, especially in rapidly growing regions with rising cancer incidence and increasing molecular testing capacity.
-
Threats:
The companion diagnostics market confronts significant threats from evolving regulatory frameworks that demand extensive clinical validation, post-market surveillance, and evidence of clinical utility, which can increase development costs and delay launches. Emerging low-cost genomic testing models, including broad tumor profiling panels offered by centralized reference labs, may commoditize certain biomarker assays and pressure pricing for single-analyte tests. Consolidation among pharmaceutical companies and large diagnostic players can intensify competitive bidding for co-development deals, marginalizing smaller kit manufacturers and niche assay developers. Data privacy regulations, constraints on cross-border transfer of genomic data, and potential reimbursement cuts for molecular pathology services also pose risks that could slow test adoption and reduce margins for hospital laboratories and commercial testing providers.
Future Outlook and Predictions
The global companion diagnostics market is expected to sustain robust double‑digit expansion over the next decade, anchored by precision oncology and the deepening integration of diagnostics into drug development. Based on ReportMines data, the market is projected to increase from 10,60 Billion in 2025 to 23,99 Billion in 2032, implying a compound annual growth rate of 12.10 percent. Over the next 5–10 years, this growth trajectory will be driven by rising cancer incidence, expanding biomarker‑guided treatment guidelines, and payers’ preference for therapies with validated stratification tools that reduce non‑responder spend.
Technologically, the market will shift from single‑marker assays toward multiplex next‑generation sequencing and comprehensive genomic profiling used as companion diagnostics. Laboratories and in vitro diagnostics companies are likely to prioritize NGS panels that cover multiple tumor types and resistance mechanisms in a single workflow. This evolution will be supported by declining sequencing costs, maturing cloud‑based bioinformatics pipelines, and standardized variant annotation, which together will make broad genomic companion diagnostics more accessible beyond top‑tier academic centers.
Liquid biopsy‑based companion diagnostics will emerge as a critical growth vector, particularly for treatment selection and longitudinal monitoring in advanced cancers. Circulating tumor DNA and circulating tumor cell assays will increasingly complement or, in some settings, substitute tissue testing when biopsies are infeasible or insufficient. Over the next decade, assay sensitivity improvements and better pre‑analytical standardization are expected to drive widespread use of plasma‑based companion diagnostics for early resistance detection and minimal residual disease assessment, changing how oncologists adjust targeted and immunotherapy regimens.
Regulatory frameworks are anticipated to become more structured and globally harmonized, reinforcing the co‑development model between pharmaceutical companies and diagnostics manufacturers. Authorities are likely to further entrench requirements that high‑impact targeted therapies launch with an approved or cleared companion diagnostic. While this will raise evidence thresholds and development costs, it will also create high barriers to entry and reward companies with strong clinical trial integration, robust real‑world evidence capabilities, and global regulatory expertise.
Economically and competitively, the market will consolidate around a group of platform leaders that can offer end‑to‑end solutions spanning assay design, regulated kits, central testing services, and data analytics. A significant portion of smaller players may reposition into niche biomarker segments, software‑driven interpretation tools, or regional distribution partnerships. At the same time, hospital systems and reference laboratories will increasingly treat companion diagnostics as strategic assets, investing in in‑house molecular capabilities and data platforms that allow them to participate in outcomes‑based contracts and generate practice‑changing real‑world evidence.
Table of Contents
- Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Companion Diagnostics Annual Sales 2017-2028
- 2.1.2 World Current & Future Analysis for Companion Diagnostics by Geographic Region, 2017, 2025 & 2032
- 2.1.3 World Current & Future Analysis for Companion Diagnostics by Country/Region, 2017,2025 & 2032
- 2.2 Companion Diagnostics Segment by Type
- Assay Kits and Reagents
- Instruments and Systems
- Software and Bioinformatics Tools
- Services
- Liquid Biopsy Tests
- Tissue-Based Tests
- 2.3 Companion Diagnostics Sales by Type
- 2.3.1 Global Companion Diagnostics Sales Market Share by Type (2017-2025)
- 2.3.2 Global Companion Diagnostics Revenue and Market Share by Type (2017-2025)
- 2.3.3 Global Companion Diagnostics Sale Price by Type (2017-2025)
- 2.4 Companion Diagnostics Segment by Application
- Oncology
- Cardiology
- Neurology
- Infectious Diseases
- Autoimmune Diseases
- Metabolic Disorders
- Respiratory Diseases
- Gastrointestinal Diseases
- 2.5 Companion Diagnostics Sales by Application
- 2.5.1 Global Companion Diagnostics Sale Market Share by Application (2020-2025)
- 2.5.2 Global Companion Diagnostics Revenue and Market Share by Application (2017-2025)
- 2.5.3 Global Companion Diagnostics Sale Price by Application (2017-2025)
Frequently Asked Questions
Find answers to common questions about this market research report